Immune Pharmaceuticals Inc
OTC:IMNPQ
Intrinsic Value
Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of IMNPQ.
Fundamental Analysis
Balance Sheet Decomposition
Immune Pharmaceuticals Inc
| Current Assets | 364k |
| Cash & Short-Term Investments | 76k |
| Other Current Assets | 288k |
| Non-Current Assets | 20.4m |
| PP&E | 97k |
| Intangibles | 20.2m |
| Other Non-Current Assets | 100k |
| Current Liabilities | 14.9m |
| Accounts Payable | 5.5m |
| Accrued Liabilities | 1.7m |
| Other Current Liabilities | 7.6m |
| Non-Current Liabilities | 5m |
| Long-Term Debt | 870k |
| Other Non-Current Liabilities | 4.1m |
Earnings Waterfall
Immune Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-14.7m
USD
|
|
Operating Income
|
-14.7m
USD
|
|
Other Expenses
|
-19.7m
USD
|
|
Net Income
|
-34.4m
USD
|
Free Cash Flow Analysis
Immune Pharmaceuticals Inc
What is Free Cash Flow?
IMNPQ Profitability Score
Profitability Due Diligence
Immune Pharmaceuticals Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Immune Pharmaceuticals Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
IMNPQ Solvency Score
Solvency Due Diligence
Immune Pharmaceuticals Inc's solvency score is 16/100. The higher the solvency score, the more solvent the company is.
Score
Immune Pharmaceuticals Inc's solvency score is 16/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMNPQ Price Targets Summary
Immune Pharmaceuticals Inc
Ownership
IMNPQ Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
IMNPQ Price
Immune Pharmaceuticals Inc
| Average Annual Return | 20.95% |
| Standard Deviation of Annual Returns | 92.07% |
| Max Drawdown | -100% |
| Market Capitalization | 2.1m USD |
| Shares Outstanding | 2 143 690 000 |
| Percentage of Shares Shorted | 3.03% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. The company is headquartered in Fort Lee, New Jersey and currently employs 7 full-time employees. The company went IPO on 2011-09-19. The company is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. The company operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The firm is developing NanoCyclo, which is a nano-encapsulated formulation of cyclosporine-A for the treatment of atopic dermatitis and psoriasis. The Company’s oncology portfolio includes Ceplene, which a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
You don't have any saved screeners yet
